Author Affiliations: Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY (Drs Antman and Heitjan) and the M. D. Anderson Cancer Center, University of Texas, Austin (Dr Hortobagyi).
Edited by Thomas C. Jefferson, MD, Contributing
Breast cancer incidence and mortality have been stable or declining
since about 1992, the first decline since statistics were available.1,2
While screening has resulted in a higher percentage of patients with
early stage disease and improved survival, mortality at 10 years exceed 60%
for those with 10 or more involved lymph nodes or large primary tumors. Virtually
all patients who initially present with or later develop metastatic breast
cancer ultimately die of their disease.3,4
Antman KH, Heitjan DF, Hortobagyi GN. High-Dose Chemotherapy for Breast Cancer. JAMA. 1999;282(18):1701–1703. doi:10.1001/jama.282.18.1701
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: